| | |

Pleural Mesothelioma Rates Remain Stagnant As Survival Improves

pleural mesothelioma rates

A new report shows pleural mesothelioma rates in the US have failed to decline as they were predicted to do, but survival is improving slightly. 

The US government began to implement tighter restrictions on asbestos in the 1970s. Researchers at the Cleveland Clinic say original projections had the incidence of pleural mesothelioma peaking in the early 2000s as a result. Pleural mesothelioma rates were supposed to decline after that.

But numbers from the National Cancer Database (NCDB) tell a different story. They suggest that, while mesothelioma survival is improving, incidence of asbestos cancer are not.

Asbestos and Malignant Mesothelioma

Malignant mesothelioma is the most serious of a range of illnesses caused by asbestos. Pleural mesothelioma is the most common type of mesothelioma. These tumors grow on the membrane around the lungs. 

As early as the 1930s, doctors started to see a mysterious lung disease among asbestos workers. In 1970, asbestos became one of the first air pollutants to be regulated under the Clean Air Act. 

Faced with rising pleural mesothelioma rates, many countries banned asbestos altogether. But US officials hoped that strict regulation would be enough. There is still no asbestos ban in the US.

Analysis of Pleural Mesothelioma Rates

The new analysis included almost 21,000 patients with pleural mesothelioma from the NCDB. The patients were diagnosed between 2004 and 2014. 

During that time, pleural mesothelioma rates did not fall as predicted. In fact, the number of cases of pleural mesothelioma rose from 1,783 to 1,961 per year. Pleural mesothelioma now  accounts for about one third of one percent (0.03%) of all cancer cases each year. 

Mesothelioma has always been more common in men and this is still true. Women make up about a fifth of all pleural mesothelioma cases. But the proportion of mesothelioma patients who are elderly has risen.

There were a few bright spots in the report on pleural mesothelioma rates. One-year mesothelioma survival was 10 percent higher in 2014 than it was in 2004. This is particularly notable since more patients are older. 

“National trends suggest that survival is slowly increasing despite an aging cohort,” writes study author Hari Keshava. 

More mesothelioma patients are also getting help now. In 2004, only 34 percent of mesothelioma patients sought treatment. By 2014, that had risen to 54 percent. 

Factors Influencing Pleural Mesothelioma Survival

The study found that some patients have better odds of survival than others. Women, younger patients, and those with the epithelioid subtype tend to live the longest.

Pleural mesothelioma rates of survival were higher in people who were treated at academic medical centers. Patients who had better health insurance and/or higher incomes also had better outcomes.

Finally, treatment that included several different types of therapies was linked to improved mesothelioma survival.

“Multimodal therapy and treatment at academic centers are modifiable risk factors associated with improved survival,” concludes the report.

Source:

Keshava, H, et al, “Largely Unchanged Annual Incidence and Overall Survival of Pleural Mesothelioma in the USA”, August 19, 2019, World Journal of Surgery, Epub ahead of print, https://link.springer.com/article/10.1007%2Fs00268-019-05132-6

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Teacher’s Diagnosis Highlights Mesothelioma Risk in Schools

    A recent mesothelioma diagnosis in the UK once again dramatically highlights the fact that even a small amount of asbestos can be deadly. Sixty-three-year-old school teacher Marion Potts of Brockenhurst died of mesothelioma in a Southampton hospital in June. According to an article in The Mirror, the Coroner recorded a verdict of “death from an industrial disease” after hearing evidence last week that Potts actually saw asbestos dust being released when she pinned work on the classroom walls. Most recently, Potts was head of the English department at Romsey School in Hampshire until her retirement two years ago. Mesothelioma is a growing threat among school teachers, administrators, maintenance workers, and even students in British schools. A government report released last…

  • |

    Study Confirms Firefighters at Elevated Risk for Mesothelioma

    A 5-year National Institute for Occupational Safety and Health (NIOSH) study of U.S. firefighters is the first to confirm what has long been suspected: Firefighters are definitely at higher risk for malignant mesothelioma. The study examined the mortality patterns and cancer incidence (including mesothelioma) among 30,000 firefighters in three major cities. The study subjects were all career firefighters who started their careers after 1950 and were followed through 2009. In order to get a diverse sample of firefighters from across the country, the study focused on firefighters from San Francisco, Chicago and Philadelphia. Comparing firefighters to a sampling of the general public, the study looked at 92 causes of death and 41 cancer incidence groupings, with a focus on 15…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • |

    Mesothelioma Still Carries Heavy Mortality Burden in U.S.

    Asbestos exposure cost Americans more than 427,000 years of potential life in the first decade of the new millennium. That figure comes from a study on mesothelioma and asbestosis – the two most deadly asbestos-related diseases – conducted by the CDC’s National Institute for Occupational Safety and Health (NIOSH). Using National Center for Health Statistics mortality data, NIOSH researchers evaluated premature deaths and “loss of potentially productive years of life” attributable to either asbestosis or mesothelioma between 1999 and 2010. The data included only people 25 years or older with an underlying cause of death listed on their death certificate of either asbestosis or malignant mesothelioma. When the figures were calculated using the normal life expectancy for each asbestosis victim…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…